2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

2:30PM-4:00PM: Abstract Number: 840

Trajectory of Multimorbidity in Rheumatoid Arthritis in a U.S. Commercial Insurance Claims Database from 2006-2015

3S078: RA – Diagnosis, Manifestations, & Outcomes I: Pulmonary & Other Comorbidities (839–844)

2:30PM-4:00PM: Abstract Number: 821

Trends in Incidence and Prevalence of Osteoarthritis in the United Kingdom: Findings from the Clinical Practice Research Datalink (CPRD)

3S074: Epidemiology & Public Health I: Risk Factors & Outcomes for Rheumatic Diseases (821–826)

2:30PM-4:00PM: Abstract Number: 853

Two-Year Progression of Facet Joint Ankylosis on Whole Spine Low-Dose CT in Patients with Radiographic Axial Spondyloarthritis

3S083: Spondyloarthritis Including Psoriatic Arthritis – Clinical I: Imaging in Axial Spondyloarthritis & Psoriatic Arthritis (851–856)

2:30PM-4:00PM: Abstract Number: 855

Which Magnetic Resonance Imaging Lesions of the Sacroiliac Joints Are of Diagnostic Value for Axial Spondyloarthritis?

3S083: Spondyloarthritis Including Psoriatic Arthritis – Clinical I: Imaging in Axial Spondyloarthritis & Psoriatic Arthritis (851–856)

4:30PM-6:00PM: Abstract Number: 943

A Phase 1b/2a Trial of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus

3S110: SLE – Clinical III: Clinical Trials II (939–944)

4:30PM-6:00PM: Abstract Number: 939

A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obinutuzumab or Placebo in Combination with Mycophenolate Mofetil in Patients with Active Class III or IV Lupus Nephritis

3S110: SLE – Clinical III: Clinical Trials II (939–944)

4:30PM-6:00PM: Abstract Number: 942

A Randomized Prospective Trial to Assess the Clinical Utility of Multianalyte Assay with Complement Activation Products in Diagnosing Systemic Lupus Erythematosus

3S110: SLE – Clinical III: Clinical Trials II (939–944)

4:30PM-6:00PM: Abstract Number: 895

A Spatial-temporal Analysis of Organ-specific Lupus Flares in Relation to Fine Particulate Matter Pollution and Temperature

3S101: Epidemiology & Public Health II: SLE (892–897)

4:30PM-6:00PM: Abstract Number: 905

A Third of Relapsing Polychondritis Patients with Ear Involvement at Presentation Had Airway Involvement at the Last Follow-up with a High Mortality Rate

3S104: Miscellaneous Rheumatic & Inflammatory Disease I: Expanding the Spectrum of Clinical Features in Rheumatological Disorders (903–908)

4:30PM-6:00PM: Abstract Number: 890

Adenosine A2A Receptor Signaling Activates FoxO1 and FoxO3 and Promotes Cartilage Autophagy

3S105: Osteoarthritis & Joint Biology – Basic Science (886–891)

4:30PM-6:00PM: Abstract Number: 920

Adenosine Deaminase 2 as a Circulating Biomarker of Macrophage Activation Syndrome

3S107: Pediatric Rheumatology – Clinical I: Systemic JIA (915–920)

4:30PM-6:00PM: Abstract Number: 955

Adherence to Statin Therapy in Rheumatoid Arthritis Patients: A Population-Based Cohort Study

3S089: Health Services Research I: Clinical Perspectives (951–956)

4:30PM-6:00PM: Abstract Number: 892

Adverse Childhood Experiences Are Associated with Systemic Lupus Erythematosus in a Clinical Population from Bronx, New York

3S101: Epidemiology & Public Health II: SLE (892–897)

4:30PM-6:00PM: Abstract Number: 949

Assessment of Femoral Vein Wall Thickness with Doppler Ultrasound Can Be a Diagnostic Tool for Behcet’s Disease

3S112: Vasculitis – Non-ANCA-Associated & Related Disorders I: Miscellaneous Disorders (945–950)

4:30PM-6:00PM: Abstract Number: 881

Auto-antibodies Targeting Components of Sarcolemma Repair: A Pathogenic Mechanism in Human Inflammatory Myopathies

3S100: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (880–885)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].